`

Tagged: Surrogate End Points

Interest is increasing rapidly in using surrogate endpoints as primary measures of the effectiveness of investigational drugs in definitive drug trials. Learn more at bbcrconsulting.com.

July 26th, 2023 | Surrogate End Points

The primary difference between a biomarker and a surrogate endpoint is that a biomarker is a “candidate” surrogate marker. In contrast, a surrogate marker is a test used and taken to measure the effects of a specific treatment. In orphan diseases and precision medicine, developing a biomarker plan during translation into early clinical development moves […]

In orphan diseases and precision medicine, developing a biomarker plan during translation into early clinical development moves treatment to market faster, and still meets the FDA’s expectations.

June 15th, 2023 | Surrogate End Points

Pin It on Pinterest